Tollys is a biopharmaceutical company focused on the biology and modulation of the TLR3 receptor to enhance innate immunity. By targeting this receptor, Tollys aims to improve immune responses against viral infections and other diseases, addressing a critical gap in current therapeutic options.
Funding
$2.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current therapeutic options often fall short in effectively enhancing innate immunity against viral infections and other diseases. There remains a critical need for innovative approaches that can modulate the TLR3 receptor to improve immune responses.
Solution
Tollys is a biopharmaceutical company that focuses on the biology and modulation of the TLR3 receptor to enhance innate immunity. By specifically targeting the TLR3 receptor, Tollys aims to develop novel therapeutics that can improve the body's natural defenses against viral infections and other diseases. This approach seeks to address the limitations of existing treatments by stimulating a more robust and targeted immune response. Tollys' research and development efforts are centered on understanding the intricate mechanisms of the TLR3 receptor and its role in immune regulation.
Target Audience
Tollys' primary customers are likely pharmaceutical companies, research institutions, and healthcare providers seeking innovative solutions for enhancing immune responses against viral infections and other diseases.
Features
- Focus on the TLR3 receptor as a key target for immune modulation.
- Development of novel therapeutics to enhance innate immunity.
- Research into the biology of the TLR3 receptor and its role in immune responses.